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Abstract
Introduction and objectives. Many epidemiological and experimental studies report a strong role of chemical carcinogens 
in the etiology of bladder cancer. However, the involvement of heavy metals in tumourigenesis of urothelial carcinoma 
of the bladder has been poorly investigated. Therefore, the aim of this study was to examine the relationship between 
chromium (Cr) and bladder cancer.  
Materials and methods. Chromium concentration in two 36-sample series of bladder cancer tissue and sera from patients 
with this neoplasm were matched with those of a control group. The amount of trace elements in every tissue sample was 
determined using atomic absorption spectrometry. This was correlated with tumour stage.  
Results. While the median chromium concentration levels reached statistically higher values in the bladder cancer tissue, 
compared with the non-cancer tissue (99.632ng/g and 33.144ng/g, respectively; p<0.001), the median Cr levels in the sera of 
the patients with this carcinoma showed no statistical difference when compared to those of the control group (0.511µg/l 
and 0.710µg/l, respectively; p=0.408). The median levels of Cr in the bladder tissue, depending on the stage of the tumour, 
compared with the tissue without the neoplasm, observed the same relationship for both non-muscle invasive and muscle-
invasive tumours (p<0.001 and p<0.01, respectively).  
Conclusions. This study shows that patients with urothelial carcinoma of the bladder had higher tissue Cr levels than 
people without tumour, while no difference was found in the Cr serum levels between the two groups of patients under 
investigation.
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INTRODUCTION
There is an emerging understanding of toxic and carcinogenic 
effects of certain heavy metals and trace elements in both 
animals and humans [1–7]. Chromium (Cr) is a known human 
carcinogen and has been hypothesized as a cause of several 
cancers, including leukaemia and neoplasms of lung, nose 
and nasal sinuses [8–10]. Moreover, there is epidemiological 
evidence suggesting that Cr is a plausible bladder carcinogen 
[11–14]. Additionally, higher Cr levels in the urine of people 
occupationally exposed to this element have been reported, 
further suggesting its possible contribution to lower urinary 
tract carcinogenesis [15]. Thus far, however, there has been 
no demonstrable direct evidence for the association of Cr 
with human urothelial carcinoma of the bladder.
In the presented study, the concentration of chromium in 
the tissue of bladder tumour was measured and compared 
with the content in non-cancerous tissue. In addition, the 
concentration of Cr in the sera of patients with bladder 
tumours were compared with control samples from patients 
with non-neoplasm- or non-heavy metal-related diseases 
of the urinary system. Finally, the resultant levels were 
evaluated, depending on the stage of the tumour.
MATERIALS AND METHOD
The study was approved by the Medical Ethics Committee 
for Human Studies of the Medical University in Bialystok, 
Poland, and all procedures were performed in accordance 
with the Helsinki Declaration of 1975, as revised in 1983. 
The study was conducted on 36 patients with histologically-
proven urothelial bladder carcinoma, with no lymph node 
involvement or distant metastases. The patients were 30 men 
aged 41–88 (average 68.5 years) and 6 women aged 52–78 
(average 67 years). Non-muscle invasive cancers (Tis – Ta 
– T1) occurred in 22 cases, and muscle-invasive tumours 
(T2 – T3 – T4) in 14 patients. The grade of histological 
malignancy, G1, G2 and G3, was found in 10, 13, and 10 
patients, respectively, whereas in 3 patients it was not possible 
to establish with certainty the actual grade of malignancy.
The tumours were removed by transurethral resection 
(TURBT) in 29 patients and by cystectomy in 7 patients. 
Just after the bladder or the tumour itself had been removed, 
samples of 1g of cancer tissue were taken and stored after 
being snap frozen in liquid nitrogen. Before bladder or 
tumour removal, three-milliliter samples of venous blood 
were collected from the basilic vein using Vacutainer 
vacuum sets.
The control material consisted of 15 one-gram samples 
of bladder tissue taken from gender-and–age-matched 
individuals who had died from trauma (n=15). Samples were 
taken during autopsy from 12 male cadavers aged 54–77 
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(average 64 years) and 3 females aged 57–76 (average 65.5 
years).
Next, 15 three-millilitre samples of venous blood from the 
corresponding gender-and-age-matched patients, who were 
in fasting states with non-neoplasm or trace elements-related 
diseases of the urinary system (1 woman with benign pelvic-
ureteric junction obstruction, 3 with stress incontinence, 3 
men with scrotal injury, 3 with renal injury, 2 with benign 
urethral stricture and 3 with hydrocele), were collected in 
Vacutainer vacuum sets and used in the control group. There 
were 11 samples taken from male patients aged 43–86 (average 
67), and 4 from females aged 52–78 (average 67.5 years). There 
was no difference between the socio-economic status of the 
cases and controls. Neither group had occupational exposure 
to chromium.
Before analysis, the samples were mineralized in 
concentrated nitric acid (V) in a UniClever closed 
microwave system manufactured by Plazmatronika. The 
mineralization products were quantitatively transferred into 
polypropylene scintillation vessels. Cr was quantitatively 
determined directly in the sera samples diluted with 0,2% 
Triton X-100. The levels of Cr concentration were analyzed 
by the atomic absorption spectrometry technique with 
the Zeeman background correction on a Hitachi Z-5000 
spectrometer. The Cr content was calculated using readings 
on a standardisation curve formed by recording differences 
in absorbance and element concentration. The accuracy of 
the Cr determination method was verified using the following 
certified standard materials: Seronorm 404108 for the whole 
blood and BCR 184 for bovine muscle. Accuracy (i.e. % of 
error) and coefficient of variation were calculated for the 
certified standards under investigation. The samples were 
evaluated in the Department of Bromatology of the Medical 
University in Bialystok, which is involved in a programme of 
intra-laboratory comparative analysis of elements, organized 
by the Institute of Chemistry and Nuclear Techniques, and 
the State Institution of Sanitation in Poland.
Since data in the studied group was not distributed in a 
Gaussian manner, the Mann-Whitney U test was used. A p 
value of < 0.05 was considered statistically significant. The 
Statistical Package for the Social Sciences (SPSS) was used 
for all statistical analyses.
RESULTS
Median values of Cr, determined in the bladder cancer tissue 
and sera of the patients with bladder tumour and the control 
group, are shown in Table 1. Figures 1–2 present Cr bladder 
tissue and serum concentration distribution of patients with 
bladder cancer and controls.
The median value of Cr concentration in the bladder cancer 
tissue and in the non-cancer tissue was 99.632ng/g and 
33.144ng/g, respectively. This increase in Cr concentration 
in cancer tissue was statistically significant (p<0.001). There 
was no significant difference in the serum Cr levels between 
the groups (0.511µg/l and 0.710µg/l, respectively; p=0.408). 
Moreover, tissue and serum Cr levels were calculated for the 
two tumour stage groups, (one with non-muscle invasive and 
the other with muscle invasive cancers). When processed by 
the non-parametric Mann-Whitney U test, the results showed 
that the median levels of Cr in the bladder tissue, depending 
on the stage of the tumour, were significantly higher for 
both non-muscle invasive and muscle-invasive tumours, 
compared with the tissue without the neoplasm (p<0.001 and 
p<0.01, respectively). There was no marked difference in the 
Cr serum levels, between people with urothelial carcinoma 
of the bladder and the controls when analysed by the two 
tumour stage groups (Tab. 2).
Table 1. Bladder tissue and serum chromium concentrations in patients 
with bladder cancer vs. controls
Group n Q1 Median Q3 p
Cr serum, 
µg/l
bladder cancer cases 36 0.353 0.511 0.920
0.408
controls 15 0.388 0.710 0.942
Cr bladder 
tissue, ng/g
bladder cancer cases 36 51.045 99.632 186.582
0.001*
controls 15 24.764 33.144 42.605
Cr – chromium; * – statistically significant; n – number of samples; Q1 – lower quartile; Q3 – 
upper quartile
Figure 2. Chromium (Cr) distribution in sera of patients with bladder cancer and 
control group
Figure 1. Chromium (Cr) distribution in bladder tissue of patients with bladder 
cancer and control group
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DISCUSSION
In the study, a statistically significant elevation of tissue 
chromium levels was observed in patients with bladder 
cancer, and no difference in the serum Cr levels between 
the two groups of patients under investigation. To the best 
of the authors’ knowledge, there has been no previous report 
on Cr concentration levels in the bladder tissue and sera of 
patients with bladder cancer and controls. However, several 
epidemiological studies have suggested an association between 
Cr exposure and the risk of urinary bladder cancer [11–14]. 
Kutze et al. in their study, found a significantly increased 
probability of developing lower urinary tract urothelial 
tumours in patients occupationally exposed to chromium/
chromate [13]. The observed relationship was confirmed in 
a multivariate logistic regression analysis, which showed a 
significant contribution of Cr to the risk of bladder cancer. 
These observations were further corroborated by the findings 
from the matched case-control study of 431patients with 
urothelial cancer of the lower urinary tract from Northern 
Germany [12]. In this report, occupational exposure to 
chromium/chromate was associated with the increased risk 
of BC (odds ratio of 1.77; 95 per cent confidence interval 
=1.06–2.97). Interesting data is provided by Stamatiou et al. 
who followed 45 patients with non-muscle invasive bladder 
cancer for a period of three years [14]. The authors observed 
an exceptionally high recurrence rate of BC (42%) in their 
sample, which occurred within a three months interval. 
Although they did not directly assessed the levels of Cr 
in the patients’ tissues, the authors hypothesized that the 
reported unusually frequent reappearance of bladder cancer 
in that group of patients could have been associated with the 
consumption of contaminated tap water containing large 
amounts of hexavalent chromium.
The aforementioned observations linking Cr to bladder 
cancer could be related to the fact that the urinary system is 
very much involved in the Cr removal process from the human 
organism, as excretion of this element occurs predominantly 
through urine [16]. Thus, whenever this element is present 
in urine, it may directly act on the urothelium, especially 
inside the bladder, which functions as a temporary reservoir 
for urine and, as such, is exposed to Cr action for a longer 
time. Of added interest is evidence suggesting that urinary 
Cr levels increase with time of occupational exposure, which 
potentially could increase the risk for developing a bladder 
neoplasm [15, 17].
The International Agency for Research on Cancers has 
classified Cr (VI) as Group I (human carcinogen), whereas Cr 
(III) as Group III (non-carcinogenic to human) [8]. Similarly, 
The United States Environment Protection Agency (EPA) 
has classified Cr in +6 oxidation state as Group A, a known 
human carcinogen, and Cr in +3 oxidation state as Group D 
(non-carcinogenic to humans) [18]. The mechanisms involved 
in chromium-induced carcinogenesis are not, however, 
completely understood. Depending on the oxidation state of 
the chromium and presence of cellular reductants, it causes a 
wide variety of DNA lesions including Cr-DNA adducts, DNA-
protein crosslinks, DNA-DNA-crosslinks, lipid peroxidation 
and oxidative damage [19, 20]. Although evidence for Cr(VI)-
induced carcinogenicity and mutagenicity has been well 
recognised, the capability of Cr(III), and in other oxidation 
states to produce free radicals in the presence of certain 
ligands, have been learnt only recently [21–24].
The exact pathological mechanisms for alterations in Cr 
tissue levels in patients with bladder carcinoma remain 
unclear. For the time being, it is difficult to say whether 
observed differences in levels of this heavy metal in tissues are 
the causative factors or the results of the neoplastic process. 
However, in the presented study, occupational exposure was 
ruled out as a cause for element alterations in both the BC 
patients and controls.
The current study found no difference in the serum Cr 
levels between the two groups of patients under investigation. 
This observation can be attributed to the fact that serum Cr 
concentration reflects current exposure rather than whole-
body burdens [15]. Therefore, absence of difference in Cr 
serum levels between subjects with bladder cancer and 
controls provides an indirect evidence that both groups of 
people had similar exposure to chromium.
North-Eastern Poland is regarded as un unpolluted region 
and has been found to have low environmental contamination 
with Cr [25].This is mainly due to a lack of anthropogenic 
sources of heavy metals, such as industrial waste, mining or 
smelting activity. Automobile exhausts, municipal effluents 
and smoking are the major sources of Cr in this area.
CONCLUSIONS
Patients with urothelial carcinoma of the urinary bladder 
show alterations in the Cr levels in tissue suggesting an 
association between this cancer and the heavy metal. Higher 
Cr levels may play a role in the induction and development 
of the bladder tumour, or may be the result of the neoplastic 
process. Further studies should assess the biological 
significance of these parameters and their relationship with 
other contributing neoplastic factors.
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